Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

10.1245/s10434-008-0045-5
Annals of Surgical Oncology 15:2749-2756 (2008)
© 2008 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Moncrieff, M. D.
Right arrow Articles by Thompson, J. F.
PubMed
Right arrow Articles by Moncrieff, M. D.
Right arrow Articles by Thompson, J. F.

Original Article

Isolated Limb Infusion for Advanced Soft Tissue Sarcoma of the Extremity

Marc D. Moncrieff, MD1,2, Hidde M. Kroon, MD1, Peter C. Kam, MD1,3, Paul D. Stalley, MB, BS1, Richard A. Scolyer, MD1,4 and John F. Thompson, MD1,2

1 The Sydney Melanoma Unit, Gloucester House, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
2 Discipline of Surgery, The University of Sydney, Sydney, NSW, Australia
3 Discipline of Anaesthetics, The University of Sydney, Sydney, NSW, Australia
4 Discipline of Pathology, The University of Sydney, Sydney, NSW, Australia

Correspondence: Address correspondence and reprint requests to: John F. Thompson, MD; E-mail: john.thompson{at}smu.org.au

Background: Isolated limb infusion (ILI) is a minimally invasive technique for delivering high-dose regional chemotherapy. We report our experience with ILI for the treatment of soft tissue sarcoma (STS).

Methods: From our prospective database, 21 patients with STS of the limb treated with ILI between 1994 and 2007 were identified. In all patients, a high-dose cytotoxic drug combination was used.

Results: There were 14 men, and the median age was 60 years (range, 18–85 years). Eighteen patients (86%) had lower limb tumors. All patients had advanced local disease. The procedure was well tolerated. Fourteen patients (67%) received ILI before definitive surgery. The overall response rate was 90% (complete response [CR] rate 57%, partial response rate 33%). The disease-specific overall survival was 61.9% (median follow-up, 28 months). Only American Joint Committee on Cancer stage was associated with overall survival. The local recurrence rate was 42%. CR and malignant fibrous histiocytoma tumor subtype were associated with a lower local recurrence rate. A lower initial skin temperature (median 35.8°C) was associated with a CR (P = .033). Patients who had a steep increase in intramuscular temperature during the procedure were more likely to have a CR (P = .055). Classification tree analysis identified patients with an initial PaO2 of ≥194 mmHg as being more likely to have a CR. Ultimately, the overall limb salvage rate was 76%.

Conclusion: The outcomes after ILI are comparable to those achieved by conventional isolated limb perfusion. ILI is a minimally invasive alternative to isolated limb perfusion for patients with advanced STS of the extremity.

Key Words: Isolated limb infusion • Soft tissue sarcoma • Melphalan • Actinomycin D • Regional chemotherapy







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society of Surgical Oncology.